||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Sinclair Pharma Share Discussion Threads
Showing 1476 to 1497 of 1500 messages
|Quality shareholders.Reassuring to be losing money along with such well respected financial heavyweights!|
|There are some well respected names in there.|
|Aye, notice they finally updated their major shareholders' listing too.
|Every little helps.........|
|Non executive buys 150/- shares at 29.125p|
|Sinclair presenting at Biotech Conference at Chiswell St tomorrow|
|Bot vs seller
|Let's see if we get any RNSs in the coming days re holdings.......|
|Big volume today.I'm thinking that the 3.7m trade reported is actually a sell at 26.5 and the stock has been partially crossed.Hopefully that's the seller done and the stock may edge higher now.|
|It does look like they have gone under 5% hence the wording, that said, it appears to be down to 116,000 shares which FIL have "Right of Recall".
Voting rights and other totals remain the same, at 5% so probably just some financial instrument (CFD) or other.
I'll drop the company an email to get the shareholder page updated.|
Buying - was that out of date?
Had below 5% 24,796,494
Now holding 5% 24,912,594|
|Looks like Fidelity have been selling, now under 5%
From Sinclair investor page
Fidelity (FIL and FMR) 29,206,708 5.9
Not huge, so may not see buy side TR1|
|Seller keeping a lid on it here...........ho hum............
Though late trades may provide a clearer picture.......|
|I noticed Singer quoted ThermiGens sales force as 65, unless they have added to cope with Silhouette it was 55?
Trade wise, I tend to look at the algo's running over a period of time, this normal confirms such large trades.
Tempted to add but too close to existing entry points.|
|That'll be a cross at the price,despite the time delay and slight volume difference.I'd like to know who's selling.Hope it's not Soros's fund,find it reassuring having them on the register.We'll know in due course.|
|Good liquidity today, easy to deal both ways in Qty......|
|"Sinclair’s interim results for the six-month period to 30th June are in line with expectations and the company’s trading update in July, with revenue of £17.3m and a strong balance sheet at period-end in spite of significant deferred consideration payments during the period. The potentially transformational US launch of Silhouette Instalift™ is ongoing since August, backed by ThermiGen’s 65-strong sales force." - N1 Singer, via Research Tree|
|Bought this morning for my SIPP, results very good, 3 to 5 years view|
|All about SPH going fwd, a yr or so out would be a fair assumption......though everything slips into place c. 2019. Margins are exceptional..........boils down to operational leverage, as your man says.....
Big buys going through now, must be a fair whack available, interesting to see if the directors stick their hands in their pockets but with their options??|
|"Sinclair has already grown since the divestment of the non-aesthetics business to a scale where it is near to EBITDA breakeven pre US investment. Conversion on incremental sales to EBITDA is very high as the relatively fixed cost base combined with high gross margins drives operational leverage."This is the key because the market would appear to be showing some exhaustion in waiting for Sinclair to turn a profit.The assumption is that after the US presence has been established,the group might have enough operational gearing to announce a profit. That's a year or so out I presume.|
|Agree, Soundboy, several decent products just beginning to come together in a world more obsessed by cosmetic enhancement than ever. If Instlift takes off in the US as it potentially may I could see one of the big boys paying (what for them would be small change) a billion dollars in a few years for it alone-given the vagaries, and demand for cosmetics, of the US market and regulatory hurdles to introducing new medicines there. But still some way to go and mgmt just need to keep doing what they are doing for now. Thermigen deal seems to be going ok. Great business-look at the profits and margins the likes of Boots make on their own stable of products. imo|
|Well, despite recent discussions with various parties re company's future, still can't see these remaining independent with potential sales growth going fwd, at 2 or 3 times current mkt cap would be nothing for the likes of Allergan etc...
Hopefully the seller will move on soon, we'll see........|